VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

September 1, 2016 updated by: Hadassah Medical Organization
We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Study Overview

Status

Withdrawn

Conditions

Study Type

Observational

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 9 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

preterm infants.

Description

Inclusion Criteria:

  • Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

  • Preterm with IVH or known infection or meningitis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
1
2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hadassah Medical Organization

Investigators

  • Principal Investigator: Talya Dor, MD, Hadassah Medical Organization

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Study Completion (Anticipated)

January 1, 2009

Study Registration Dates

First Submitted

November 25, 2007

First Submitted That Met QC Criteria

November 26, 2007

First Posted (Estimate)

November 27, 2007

Study Record Updates

Last Update Posted (Estimate)

September 2, 2016

Last Update Submitted That Met QC Criteria

September 1, 2016

Last Verified

November 1, 2007

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 606060-HMO-CTIL

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Infants With White Matter Damage

  • First Affiliated Hospital Xi'an Jiaotong University
    The First Affiliated Hospital of Henan University of Traditional Chinese... and other collaborators
    Not yet recruiting
    Predicting Cerebral Palsy in Infants With White Matter Injury Using MRI
    Cerebral Palsy | Periventricular White Matter Abnormalities
    China
  • Sheba Medical Center
    Tel Aviv University
    Unknown
    The Effect of Exposure to Maternal Human Milk Odor on Physiological State of Preterms.
    Health Preterm Infants With no Active Disease | Human Milk Nutrition | Incubator Stay
    Israel
  • Hugo W. Moser Research Institute at Kennedy Krieger...
    Recruiting
    Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)
    Leukoencephalopathies | Genetic Disease | White Matter Disease | Ataxia, Cerebellar | LBSL | Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation
    United States
  • Mayo Clinic
    Recruiting
    Retina is a Marker for Cerebrovascular Heath
    Cerebral Small Vessel Diseases | Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy | Cerebral Microbleeding | Sporadic White Matter Disease
    United States
  • University College Cork
    Karolinska Institutet; University of Pisa; Göteborg University; The Rotunda Hospital and other collaborators
    Recruiting
    Assessing Intellectual and Motor Outcomes in High-risk Infants (AIM-High)
    Cerebral Palsy | Cerebral Palsy (CP) | Preterm | Prematurity; Extreme | Cognitive Development | Motor Impairment | Cerebral Palsy Children | HIE - Hypoxic - Ischemic Encephalopathy | High-risk Infants | Intellectual and Developmental Disabilities
    Ireland
  • Children's Hospital of Philadelphia
    Eli Lilly and Company; University of Pennsylvania; Takeda; National Institute of... and other collaborators
    Recruiting
    The Myelin Disorders Biorepository Project (MDBP)
    Mucopolysaccharidoses | Leukoencephalopathies | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2... and other conditions
    United States
  • Children's Hospital of Philadelphia
    Illumina, Inc.
    Completed
    LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
    Mucopolysaccharidoses | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2 Gangliosidosis | Zellweger... and other conditions
    United States

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe